Revisiting the role of measurable residual disease in FLT3 mutated acute myelogenous leukemia

References

• DiNardo CD, Erba HP, Freeman SD, et al. Acute myeloid leukaemia. Lancet. 2023;401(10393):2073–2086. doi: 10.1016/S0140-6736(23)00108-3
   PubMed Web of Science ®Google Scholar
• Dohner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377. doi: 10.1182/blood.2022016867
   PubMed Web of Science ®Google Scholar
• Reikvam H. Revisiting the prognostic role of FLT3 mutations in acute myelogenous leukemia. Expert Rev Hematol. 2023;16(5):317–323. doi: 10.1080/17474086.2023.2202849
   PubMed Web of Science ®Google Scholar
• Heuser M, Freeman SD, Ossenkoppele GJ, et al. 2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD working party. Blood. 2021;138(26):2753–2767. doi: 10.1182/blood.2021013626
   PubMed Web of Science ®Google Scholar
• Blachly JS, Walter RB, Hourigan CS. The present and future of measurable residual disease testing in acute myeloid leukemia. Haematologica. 2022;107(12):2810–2822. doi: 10.3324/haematol.2022.282034
   PubMed Web of Science ®Google Scholar
• Ivey A, Hills RK, Simpson MA, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374(5):422–433. doi: 10.1056/NEJMoa1507471
   PubMed Web of Science ®Google Scholar
• Jahn N, Jahn E, Saadati M, et al. Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial. Leukemia. 2022;36(9):2218–2227. doi: 10.1038/s41375-022-01650-w
   PubMed Web of Science ®Google Scholar
• Othman J, Potter N, Mokretar K, et al. FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML. Leukemia. 2023;37(10):2066–2072. doi: 10.1038/s41375-023-01994-x
   PubMed Web of Science ®Google Scholar
• Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377. doi: 10.1182/blood.2022016867
   PubMed Web of Science ®Google Scholar
• Cocciardi S, Dolnik A, Kapp-Schwoerer S, et al. Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. Nat Commun. 2019;10(1):2031. doi: 10.1038/s41467-019-09745-2
   PubMedGoogle Scholar
• Rohnert MA, Kramer M, Schadt J, et al. Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia. Leukemia. 2022;36(9):2208–2217. doi: 10.1038/s41375-022-01647-5
   PubMed Web of Science ®Google Scholar
• Dix C, Lo TH, Clark G, et al. Measurable residual disease in acute myeloid leukemia using flow cytometry: a review of where we are and where we are going. J Clin Med. 2020;9(6):1714. doi: 10.3390/jcm9061714
   PubMed Web of Science ®Google Scholar
• Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378(13):1189–1199. doi: 10.1056/NEJMoa1716863
   PubMed Web of Science ®Google Scholar
• Gaballa S, Saliba R, Oran B, et al. Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. Am J Hematol. 2017;92(4):331–337. doi: 10.1002/ajh.24632.
   PubMed Web of Science ®Google Scholar
• Lee JM, Park S, Hwang I, et al. FLT3-ITD measurable residual disease monitoring in acute myeloid leukemia using next-generation sequencing. Cancers (Basel). 2022;14(24). doi: 10.3390/cancers14246121
   Web of Science ®Google Scholar
• Blatte TJ, Schmalbrock LK, Skambraks S, et al. getITD for FLT3-ITD-based MRD monitoring in AML. Leukemia. 2019;33(10):2535–2539. doi: 10.1038/s41375-019-0483-z
   PubMed Web of Science ®Google Scholar
• Loo S, Dillon R, Ivey A, et al. Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome. Blood. 2022;140(22):2407–2411. doi: 10.1182/blood.2022016567
   PubMed Web of Science ®Google Scholar
• Dillon LW, Gui G, Page KM, et al. DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant. JAMA. 2023;329(9):745–755. doi: 10.1001/jama.2023.1363
   PubMed Web of Science ®Google Scholar
• Grob T, Sanders MA, Vonk CM, et al. Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia. J Clin Oncol. 2023;41(4):756–765. doi: 10.1200/JCO.22.00715
   PubMed Web of Science ®Google Scholar
• Perl AE, Erba H, Montesinos P, et al. Quantum-first trial: FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–Specific measurable residual disease (MRD) clearance assessed through induction (IND) and consolidation (CONS) is associated with improved overall survival (OS) in newly diagnosed (nd) FLT3-ITD+ AML patients (pts). ASH Annual Meeting & Exposition, Abstract no 832; San Diego, CA, US; 2023.
   Google Scholar
• Rucker FG, Bullinger L, Cocciardi S, et al. Next-generation sequencing-based measurable residual disease monitoring in acute myeloid leukemia with FLT3internal tandem duplication treated with intensive chemotherapy plus midostaurin. European Hematology Association Hybrid Congress 2023, Abstract no S135; Frankfurt, Germany; 2023.
   Google Scholar
• Levis MJ. ilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3. J Clin Oncol. 2024. Epub ahead of print.
   Google Scholar
• Thol F, Gabdoulline R, Liebich A, et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018;132(16):1703–1713. doi: 10.1182/blood-2018-02-829911
   PubMed Web of Science ®Google Scholar